Which calcium channel blocker is indicated for chronic stable angina and Raynaud's phenomenon?

Nifedipine is a calcium channel blocker that is effective for treating chronic stable angina and is also indicated for managing Raynaud's phenomenon. The mechanism of action for nifedipine involves the relaxation of vascular smooth muscle, which leads to vasodilation and reduced vascular resistance. This vasodilatory effect is beneficial in both conditions; it decreases the workload on the heart in angina by improving blood flow while also alleviating symptoms of Raynaud’s phenomenon, which is characterized by excessive vasospasm in response to cold or stress.

Nifedipine is particularly effective in the management of these conditions due to its ability to dilate peripheral and coronary blood vessels, enhancing blood supply to the heart and peripheral tissues. In contrast, other options like Norvasc (amlodipine) and Nisoldipine may also be used for angina and vascular issues, but they may not be specifically indicated in the context of both chronic stable angina and Raynaud's phenomenon as nifedipine is. Clevidipine, being an ultra-short-acting calcium channel blocker primarily used for hypertension, is not indicated for these chronic conditions.

In summary, nifedipine is the most appropriate choice because it effectively addresses the